Ana Gimenez-Capitan
Overview
Explore the profile of Ana Gimenez-Capitan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
51
Citations
1288
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rosell R, Santarpia M, Pedraz-Valdunciel C, Ciappina G, Aguilar A, Gimenez-Capitan A, et al.
J Liq Biopsy
. 2025 Mar;
1:100001.
PMID: 40027282
Lung cancer screening programs, particularly in the UK, have shown a decrease in lung cancer-related deaths among individuals who underwent low-dose computed tomography (CT) screening. Researchers are now focusing on...
2.
Garcia-Roman S, Garzon-Ibanez M, Bertran-Alamillo J, Jordana-Ariza N, Gimenez-Capitan A, Garcia-Pelaez B, et al.
Transl Oncol
. 2024 Jan;
40:101878.
PMID: 38183801
Background: The EGFR pathway is involved in intrinsic and acquired resistance to a wide variety of targeted therapies in cancer. Vaccination represents an alternative to the administration of anti-EGFR monoclonal...
3.
Pedraz-Valdunciel C, Ito M, Giannoukakos S, Gimenez-Capitan A, Molina-Vila M, Rosell R
JTO Clin Res Rep
. 2024 Jan;
4(12):100604.
PMID: 38162176
Introduction: As recently evidenced by the ADAURA trial, most patients with stages IB to IIIA of resected EGFR-mutant lung adenocarcinoma benefit from osimertinib as adjuvant therapy. Nevertheless, predictive markers of...
4.
Rosell R, Codony-Servat J, Gonzalez J, Santarpia M, Jain A, Shivamallu C, et al.
Crit Rev Oncol Hematol
. 2023 Dec;
195:104228.
PMID: 38072173
KRAS G12C mutations in non-small cell lung cancer (NSCLC) partially respond to KRAS G12C covalent inhibitors. However, early adaptive resistance occurs due to rewiring of signaling pathways, activating receptor tyrosine...
5.
Verges C, Gimenez-Capitan A, Ribas V, Salgado-Borges J, March de Ribot F, Mayo-de-Las-Casas C, et al.
Ocul Surf
. 2023 Jul;
30:42-50.
PMID: 37524297
Background: Meibomian gland dysfunction (MGD) is one of the most common conditions in ophthalmic practice and the most frequent cause of evaporative dry eye disease (DED). However, the immune mechanisms...
6.
Bertran-Alamillo J, Gimenez-Capitan A, Roman R, Talbot S, Whiteley R, Floch N, et al.
Mol Cancer
. 2023 Jul;
22(1):110.
PMID: 37443114
Background: Drugs targeting the spindle assembly checkpoint (SAC), such as inhibitors of Aurora kinase B (AURKB) and dual specific protein kinase TTK, are in different stages of clinical development. However,...
7.
Gimenez-Capitan A, Sanchez-Herrero E, Robado de Lope L, Aguilar-Hernandez A, Sullivan I, Calvo V, et al.
Mol Oncol
. 2023 May;
17(9):1884-1897.
PMID: 37243883
ALK, ROS1, and RET fusions and MET∆ex14 variant associate with response to targeted therapies in non-small-cell lung cancer (NSCLC). Technologies for fusion testing in tissue must be adapted to liquid...
8.
DAmbrosi S, Giannoukakos S, Antunes-Ferreira M, Pedraz-Valdunciel C, Bracht J, Potie N, et al.
Int J Mol Sci
. 2023 Mar;
24(5).
PMID: 36902312
Despite the diversity of liquid biopsy transcriptomic repertoire, numerous studies often exploit only a single RNA type signature for diagnostic biomarker potential. This frequently results in insufficient sensitivity and specificity...
9.
Karachaliou N, Codony-Servat J, Teixido C, Pilotto S, Drozdowskyj A, Codony-Servat C, et al.
Sci Rep
. 2023 Mar;
13(1):3620.
PMID: 36869103
No abstract available.
10.
Pedraz-Valdunciel C, Giannoukakos S, Gimenez-Capitan A, Fortunato D, Filipska M, Bertran-Alamillo J, et al.
Pharmaceutics
. 2022 Oct;
14(10).
PMID: 36297470
Background: The analysis of liquid biopsies brings new opportunities in the precision oncology field. Under this context, extracellular vesicle circular RNAs (EV-circRNAs) have gained interest as biomarkers for lung cancer...